27 May 2013
: Case report
Adalimumab (Humira) induced acute lung injury
Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy
Ritesh KohliEFG, Karim NamekEFDOI: 10.12659/AJCR.889200
Am J Case Rep 2013; 14:173-175
Abstract
Background: Adalimumab is a recombinant human monoclonal antibody that blocks the effects of tumor necrosis factor-alpha. Adalimumab related acute lung injury is a rare form of acute respiratory distress syndrome of possible immune etiology that develops immediately after an infusion.
Case Report: We describe a 78 year old, male with no previous cardiac comorbidities, who developed acute lung injury (ALI) within one hour of administration of adalimumab. He was successfully treated with mechanical ventilatory support and adjuvant therapy.
Conclusions: TNFalpha antagonists are a part of a new and revolutionary treatment for severe and difficult-to-treat autoimmune and inflammatory diseases.This report emphasizes that this fatal complication may occur with use of this drug.Clinicians need to be aware of this condition as prompt recognition and supportive management can prevent unwanted morbidity and mortality.
Keywords: acute lung injury, adalimumab, Anti-Inflammatory Agents - adverse effects, Respiratory Distress Syndrome, Adult
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949194
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948731
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947386
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948268
Most Viewed Current Articles
21 Jun 2024 : Case report
101,937
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
54,506
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
38,182
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,994
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200